LOS ANGELES, Apr. 16, 2014 /PRNewswire/ -- Medbox, Inc.
(OTCQB: MDBX) (www.medbox.com), a leader in providing ancillary
services to the alternative medicine industry, dispensary
consulting services, and patented medicine dispensing systems to
medical and retail industries, today announced creation of a
shareholder due diligence and Q&A page on the company's
website.
The purpose of the web content is to help answer questions
received from shareholders, potential shareholders and
investigative journalists in an outwardly transparent manner.
"The point is setting the standard for all companies to follow
in our industry," stated Vincent
Mehdizadeh, Senior Strategist and Founder at Medbox. "The
high profile that the industry and market has awarded us makes us a
target for overzealous and sometimes unscrupulous 'Short
Journalists' that will ask questions, distort company responses,
and publish content that is misleading and factually inaccurate.
This strategy will enable Medbox to document questions that are
presented to us and that we feel warrant a response. That is the
level of transparency the investment community deserves."
In addition, recently, a few public companies in the marijuana
industry had trading suspended by the SEC due to a lack of
"adequacy and accuracy of information" about their companies.
"We are a new SEC filer and strive to bring legitimacy to this
new industry as it is taking shape," stated Dr. Bruce Bedrick CEO
of Medbox. "As a company, we take pride in the steps we have taken
to get here and the steps we will ultimately take to reach our next
goals of capturing additional revenue, maintaining shareholder
value through our dynamic and disruptive technologies, and also
thinking outside the box as to shareholder communications. We have
a great rapport with our shareholders and it is an honor serving
them and building our brand."
The Due Diligence Q&A can be found on the company's website
by clicking here or by visiting the company's website and clicking
on the Investor DD tab on the top navigation menu. The section may
be updated quarterly with additional questions and answers at the
company's discretion. Interested parties may submit questions to
hart@haydenir.com for further handling and consideration.
About Medbox,
Inc:
Medbox is a leader in the development, sales and service of
automated, biometrically controlled dispensing and storage systems
for medicine and merchandise. Headquartered in Los Angeles, Medbox, through its wholly owned
subsidiary, Medicine Dispensing Systems, offers their patented
systems, software and consulting services to pharmacies,
alternative medicine dispensaries and local governments in the U.S.
In addition, through its wholly owned subsidiary, Vaporfection
International, Inc. (www.vaporfection.com), the company offers an
industry award winning medical vaporizer product. Medbox, through
its newly established subsidiaries, also engages in the following
ancillary services catered to the alternative medicine industry:
merchant services and armored transport for cash deposits,
cannabidiol R&D, real estate acquisitions and subsequent lease
programs to alternative medicine dispensaries, and also alternative
medicine dispensary management services.
Medbox, Inc. is a publicly traded company, and is quoted on the
OTCQB, ticker symbol MDBX.
Forward-Looking Statements: The statements in this press
release constitute forward-looking statements within the meaning of
federal securities laws. Such statements are based on our current
beliefs and expectations and are inherently subject to significant
business, economic and competitive uncertainties and contingencies,
many of which are beyond our control. In addition, such
forward-looking statements are subject to assumptions with respect
to future business strategies and decisions that are subject to
change. Potential risks and uncertainties include, but are not
limited to, technical advances in the industry as well as political
and economic conditions present within the industry. We do not take
any obligation to update any forward-looking statement to reflect
events or developments after a forward-looking statement was
made.
For more information on Medbox, please contact the company at
(800) 762-1452 or go online to www.medbox.com.
For additional due diligence information, visit
http://www.thedispensingsolution.com/investors
Contacts:
Investor Relations
Stephen Hart
Hayden IR
+1- 917-658-7878
hart@haydenir.com
SOURCE Medbox, Inc.